| Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. | Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J, Hong Z, Zhang J, Zheng S, Wan F, Liu Z, Dai B. | 03/5/2024 |
| Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling. | Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J, Wan F, Zhang J, Zheng S, Yang Y, Hong Z, Dai B. | 06/15/2023 |
| SMYD2 Expression: Its Relationship to Cytogenetic and Prognosis in a Newly Diagnosed Childhood B-Acute Lymphoblastic Leukemia. | SMYD2 Expression: Its Relationship to Cytogenetic and Prognosis in a Newly Diagnosed Childhood B-Acute Lymphoblastic Leukemia.
Gawdat RM, Khalil SA, Hassan NM, Nabil R, Alazhary NM. | 03/14/2023 |
| SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis. | SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Xu K, Ding J, Zhou L, Li D, Luo J, Wang W, Shang M, Lin B, Zhou L, Zheng S., Free PMC Article | 01/21/2023 |
| The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization. | The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
Dashti P, van de Peppel J, Thaler R, Paradise CR, Stein GS, Montecino MA, van Leeuwen JPTM, van der Eerden BJ, Dudakovic A, van Wijnen AJ. | 12/3/2022 |
| Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer. | Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer.
Alshammari E, Zhang YX, Yang Z., Free PMC Article | 10/8/2022 |
| Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties. | Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties.
Li X, Wang Y, Zhang Y, Liu B. | 08/27/2022 |
| SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer. | SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Lai Y, Yang Y. | 08/27/2022 |
| STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells. | STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.
Pan K, Hu B, Wang L, Yuan J, Xu W. | 08/27/2022 |
| SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth. | SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth.
Pan L, Fan Y, Zhou L. | 08/20/2022 |
| SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells. | SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells.
Yu YQ, Herrmann A, Thonn V, Cordsmeier A, Neurath MF, Ensser A, Becker C., Free PMC Article | 05/7/2022 |
| Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications. | Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T. | 02/26/2022 |
| The ribosomal protein eL21 interacts with the protein lysine methyltransferase SMYD2 and regulates its steady state levels. | The ribosomal protein eL21 interacts with the protein lysine methyltransferase SMYD2 and regulates its steady state levels.
Khan MIK, Charles RCM, Ramachandran R, Gupta S, Govindaraju G, Mishra R, Rajavelu A, Coumar MS, Chavali S, Dhayalan A. | 12/4/2021 |
| SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. | SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y, Yang L., Free PMC Article | 10/16/2021 |
| SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer. | SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
Wang Y, Jin G, Guo Y, Cao Y, Niu S, Fan X, Zhang J. | 10/2/2021 |
| Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia. | Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia.
Zhang P, Ruan J, Weng W, Tang Y. | 05/8/2021 |
| Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates. | Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
Weirich S, Schuhmacher MK, Kudithipudi S, Lungu C, Ferguson AD, Jeltsch A., Free PMC Article | 01/9/2021 |
| Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. | Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y, Qiu R, Yang Y, Gao T, Zheng Y, Huang W, Gao J, Zhang K, Liu R, Wang S, Hou Y, Yu W, Leng S, Feng D, Liu W, Zhang X, Wang Y. | 09/26/2020 |
| Results reveal that the histone methyltransferase SMYD2 is dispensable in the undifferentiated hESCs and the early neuroectodermal differentiation, but it promotes the mesendodermal differentiation of hESCs through the epigenetic control of critical genes to mesendodermal lineage commitment. | SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.
Bai HJ, Zhang P, Ma L, Liang H, Wei G, Yang HT. | 07/18/2020 |
| The recent surge of data on SMYD2 structure and function highlights that SMYD2 is a critical regulator of cardiovascular disease and cancer. Most studies have demonstrated that SMYD2 methylates nonhistone proteins to achieve its function, which is consistent with the fact that SMYD2 primarily localizes to the cytoplasm. [review] | Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X, Jiang XJ, Fang ZM., Free PMC Article | 06/20/2020 |
| The expression of SMYD2 can be upregulated by IL-6-STAT3 and TNFalpha-NF-kappaB signaling, which integrates epigenetic regulation to inflammation in triple-negative breast cancer development. | Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX, Zhou JX, Calvet JP, Godwin AK, Jensen RA, Li X., Free PMC Article | 11/30/2019 |
| Germline SMYD2 alleles are associated with bad clinical outcome of first-line platinum-based treatment in advanced Non-Small-Cell-Lung-Cancer patients and might be used as prognostic signature directing patient stratification and the choice of therapy. | Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I, Guindo M, Duran X, Calabuig-Fariñas S, Mercader JM, Ramirez JL, Rosell R, Torrents D, Carreras A, Kohno T, Jantus-Lewintre E, Camps C, Perucho M, Sumoy L, Yokota J, de Cid R. | 06/8/2019 |
| the observed complex formation between SMYD2 and HSP90/P23 may contribute to ERalpha regulation. | A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor α methylation by the lysine methyltransferase SMYD2.
Obermann WMJ., Free PMC Article | 03/23/2019 |
| Study shows a significant association between the methylation status of CpGs in the SMYD2 promoter and SMYD2 gene decreased expression in abdominal aortic aneurysm. | SMYD2 promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) and SMYD2 expression in vascular smooth muscle cells.
Toghill BJ, Saratzis A, Freeman PJ, Sylvius N, UKAGS collaborators, Bown MJ., Free PMC Article | 03/2/2019 |
| We found that SMYD2 expression was significantly related to tumor size (P<0.001), lymph node metastasis (P<0.005), and TNM stage (P<0.005). However, no correlations were found between SMYD2 expression and patient age, sex, thyroid capsular invasion (TCI), or extrathyroidal extension (all P>0.05). | Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W, Chen F, Fei X, Yang X, Lu X., Free PMC Article | 01/12/2019 |